Blue Arbor Raises $10.5M Series A for Prosthetic Control

A small graft of muscle gives Blue Arbor Technologies a starting point for controlling a robotic hand. In the research behind the Michigan company, living tissue helps turn a person's intention to move into signals an engineered limb can use, bringing reconstructive surgery into the design of the control system.

Blue Arbor announced the close of a $10.5M Series A on October 28, 2026, led by strategic partner Ottobock. The Grass Lake company plans to fund feasibility work, pursue U.S. clinical studies of its RESTORE External Sensing Unit and begin developing a fully implantable version. RESTORE remains investigational, with no commercial approval or clearance.

The financing connects a maker of advanced prosthetic limbs to the biological interface through which those limbs receive instructions. For the prosthetics industry, that relationship puts usability inside the investment decision: an additional mechanical capability becomes meaningful when a wearer can reliably ask for it.

How Blue Arbor connects human intent to a prosthesis

The University of Michigan's account of regenerative peripheral nerve interface research explains the biological foundation. After an amputation, peripheral nerves can continue carrying instructions associated with the missing limb. Researchers attach small muscle grafts to severed nerve ends, creating regenerative peripheral nerve interfaces, or RPNIs, whose electrical activity can be recorded and used for prosthetic control.

That arrangement gives engineers a different input to work with. The university describes muscle tissue amplifying signals that can then be interpreted by control algorithms, linking a surgical procedure to the behavior of a robotic hand. Its research report concerns earlier academic studies; it provides context for the interface rather than a claim about commercial RESTORE performance.

Blue Arbor's current External Sensing Unit, or ESU, is worn outside the body and connects through the skin to implanted electrodes. The company's product description says the device collects biological motor commands and communicates with a receiver in the prosthetic hand. Ottobock describes the processing of recorded signals into movement commands, with independent and simultaneous finger, wrist and elbow control as the intended capability.

The route from tissue to machinery helps explain the company's combination of clinical and engineering leadership. The work must account for where the signals come from, how they are captured and how a prosthesis responds to them. Each part has to fit around the person who will use the system.

What Ottobock's Series A participation brings into view

Ottobock announced a USD $5M investment in February, alongside a board seat and a strategic relationship with Blue Arbor. Blue Arbor's own February announcement identified that investment as the beginning of the Series A. October's $10.5M figure describes the round's announced close, so the two amounts should not be added together.

For Ottobock, the relationship extends its involvement into an interface that could affect how people control the prostheses it supplies. That is a practical investment logic grounded in the companies' existing work together. A manufacturer can improve the mechanics of a limb while also supporting the development of the signals needed to operate it.

Ottobock's February release reported that a first procedure at the Medical University of Vienna took place in December 2025, followed within days by functional use with an Ottobock prosthesis. Blue Arbor's October announcement reports two human implantations, including a second ESU procedure in Vienna. These are company and partner accounts of early development experience, with broader clinical evaluation still ahead.

The relationship also creates a useful perspective for operators watching medical-device partnerships. Product development can cross institutional boundaries, involving surgical researchers, an interface company and an established equipment manufacturer. In this case, the investment makes that connection visible well before commercial distribution of RESTORE.

The founders' research meets medical-device execution

Blue Arbor identifies President Paul Cederna, CMO Theodore Kung and CTO Alex Vaskov as its three founders. CEO Tod Borton leads the business alongside them. Their roles span surgical practice, neuromuscular research, control engineering and medical-device development, reflecting the range of work inside a product that connects implanted electrodes to an external prosthesis.

University of Michigan commercialization records describe Blue Arbor's purpose as commercializing regenerative peripheral nerve interface technology for advanced prosthetic control. The records list technologies involving signal interpretation and electrode interfaces. That academic lineage gives the company a substantial research context without turning university grant funding into a measure of corporate venture capital raised.

The company is pursuing two product configurations. The externally worn ESU is the focus of current feasibility work and the proposed U.S. clinical-study path. A fully implantable Internal Sensing Unit, or ISU, is a development objective, rather than an available replacement for the ESU.

For the ESU, the development path includes the externally worn device and the implanted electrodes it connects to. Moving toward the ISU would bring the sensing unit inside the body as well. Blue Arbor is financing that additional engineering effort alongside the clinical program around its first configuration.

Clinical development is the next funded assignment

Blue Arbor says proceeds will support completion of feasibility studies and pursuit of an FDA Investigational Device Exemption for U.S. ESU studies. The FDA's IDE framework governs investigational clinical work, while marketing authorization is a separate step. The announcement does not provide a commercial launch date.

The company also reports FDA Breakthrough Device designation and participation in the agency's Total Product Life Cycle Advisory Program Pilot. The FDA's description of its Breakthrough Devices Program explains that the program supports development and review while preserving safety and effectiveness standards for marketing authorization. The designation should therefore be read in the context of development, rather than as permission to sell RESTORE.

For the people building the interface, the financing brings the next clinical questions closer to the product. Surgical teams will be working with a system whose value depends on how biological signals become useful movement commands. Ottobock's participation keeps the manufacturer of the limb close to that work, as Blue Arbor develops the connection a wearer will eventually depend on.